INDIVUMED THERAPEUTICS
LIVE

Serial Number

79392961

Owner

Indivumed GmbH

Attorney

R. Glenn Schroeder

Filing Date

Feb 22, 2024

Add to watchlist:

No watchlists yet
View on USPTO

INDIVUMED THERAPEUTICS Trademark

Serial Number: 79392961 • Registration: 8190639

INDIVUMED THERAPEUTICS is a trademark filed by Indivumed GmbH on February 22, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Indivumed GmbH (5 trademarks)

Falkenried 88

Entity Type: 27

Trademark Details

Filing Date

February 22, 2024

Registration Date

March 31, 2026

Published for Opposition

February 10, 2026

Goods & Services

Pharmaceutical, therapeutic and veterinary preparations, in particular medicines for human beings and animals for the treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; human and animal sample materials, for medical purposes, namely, Allograft or Xenograft tissue preparations, tissue cuts, blood plasma, blood serum, ascites, cerebrospinal fluid, human and animal urine and human and animal stool; test kits of human and animal samples materials for medical purposes comprising medical diagnostic reagents for medical diagnostic purposes; therapeutic preparations for the treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system, made using molecular biological, molecular genetic, genetic engineering, immunological and biotechnical methods; medical diagnostic reagents; clinical diagnostic reagents for medical use; medical diagnostic test strips for blood analysis and urine analysis; diagnostic preparations and materials for medical or veterinary purposes; diagnostic reagents for medical use; diagnostic substances for medical use; biological material collections, namely, biological tissue samples, blood plasma samples and blood serum samples for medical purposes; cancer material collections, namely, biological tissue samples, blood plasma samples and blood serum samples for cancer diagnosis and treatment purposes; medical sample collections; biological sample collections, namely, biological tissue samples, blood plasma samples and blood serum samples for medical purposes; biopsy material collections, namely, biological tissue samples; all the afore-mentioned in particular with regard to the field of oncology

Scientific and technological services, namely, scientific research and design for others in the field of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; research services in the field of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; design and development of computer hardware and software, in particular computer programs; scientific research for medical purposes, in particular molecular biological, immunological and histological laboratory services, in particular research and development in the field of human medical and veterinary medical diagnostics and therapy; typing of tissue and tissue samples, in particular using molecular biological, immunological, genetic engineering and histological methods for research purposes; collection of human and animal biospecimen and clinical data for the diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; generation of, by means of scientific computer-aided sample analysis, and provision of, by means of cloud storage and online access of multi-omics data from human and animal biospecimen, in particular genomic, epigenomic, proteomic, phosphorproteomic, RNA, transcriptomic, lipidomic and metabolomic data for the diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; medical research laboratory services, namely, typing of tissue and tissue samples, in particular using molecular biological, immunological, genetic engineering and histological methods; database design and development; providing online non-downloadable computer software platforms for hosting databases; installation, maintenance and updating of database software; providing scientific research information and results in the field of diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system from an online searchable database; programming of databases; collecting genetic, medical, biomedical, biologic, chemical and biochemical data and information, in particular information generated through the use of imaging techniques, the use of liquid biopsy methods, the use of histopathological analysis and procedures, the use of genetic analysis and the use of genomics, proteomics, transcriptomics, metabolomics, lipidomics and/or glycomics studies and analysis for medical research; scientific and laboratory analysis using bioinformatics and computational biology in the field of diagnosis and treatment of cancer, metabolic diseases, cardiovascular diseases, inflammatory diseases, diseases of the immune system; consultancy relating to research and development in the field of therapeutics and pharmaceutics; pharmaceutical and therapeutical products development; pharmaceutical research and development services; research and development for the pharmaceutical and biotechnological industry; services for research and development in the pharmaceutical and biotechnical field; services for research and development regarding pharmaceutics, therapeutics, diagnostics, especially for the medical examination and medical care of patients

Apparatus and instruments for scientific research in laboratories, in particular apparatus for analysis of biologic samples and for the qualitative and quantitative recognition of analytes in samples, and the identification of sample types, namely, electronic analysers and analysers for the qualitative and quantitative recognition of samples and identification of the sample type and molecular states; apparatus for the typing of tissues and tissue samples, namely for the molecular analysis of biological samples such as tissue, cuts, blood, serum, plasma, ascites, cerebrospinal fluid, urine or stool; apparatus for recording, transmission or reproduction of data, namely, hard disk drives, blank hard computer discs, solid-state drives, and USB hardware; blank magnetic data carriers, data processing equipment and computers

Medical analysis in connection with the treatment of individuals, namely, medical analysis of X-rays and blood samples, namely, medical testing for diagnostic and treatment purposes; provision of analysis files which provide medical information to medical and scientific personnel and allows members to update their medical treatment or scientific research plans; medical clinic services; pharmaceutical advisory services; medical analysis services using bioinformatics and computational biology, for patient diagnostic and treatment purposes; providing supporting services and advice to hospitals and other medical care centers, namely, collecting and stabilizing of human and animal biospecimens, and the collection of related clinical data for patient diagnostic and treatment purposes; all the afore-mentioned in particular with regard to the field of oncology

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 30, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 31, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 31, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 20, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 20, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 20, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 20, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 20, 2026 CNEA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 19, 2025 OPNX
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 3, 2025 GNFN
FINAL REFUSAL E-MAILED
Sep 3, 2025 GNFR
FINAL REFUSAL WRITTEN
Sep 3, 2025 CNFR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 3, 2025 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 25, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 25, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 25, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 6, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 6, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 6, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 31, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 31, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 31, 2024 TROA
REFUSAL PROCESSED BY IB
Oct 19, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 27, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 27, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 25, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 24, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 11, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 12, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 8, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 4, 2024 REPR